LTGO

Latigo Biotherapeutics, Inc.

Nasdaq· CIK 0002056611 Biotech & Drug Discovery

$15.26 +0.24 (+1.60%)

Oct 26 4:00 PM ET · prev $15.02

Market cap

$1.1B

Small cap

Consensus

Buy

88% Buy or better · 8 analysts

Median target

$50.00

+228% · range $36.00–73.00

Since first trade

−16.4%

from $18.25 · Aug 7

30 days

−12.7%

from $17.48

Range since listing

$14.00–25.00

−39% from high · low Oct 14

Avg volume 20D

310.7K

Sep 29 spike 955.2K

Short interest

🔒 Subscribers only

Insider net

+$5.0M

2 buyers · 0 sellers · since Aug 10

Filing reports

analyzed by SecBot

SecBot read BULLISH 15 reports · 90 days

Balance 0 bearish · 7 bullish · 8 neutral oldest → newest, height = score

Avg score

·High conf. 11/15

Strongest BULLISH Latigo Biotherapeutics reported Q2 2026 results with a net loss of $25.8M (EPS -$27.59 vs consensus -$0.46…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

E Aug 7 Offering: Latigo Biotherapeutics Announces Pricing of Upsized $345.6…
B Aug 10 2 insiders buy $5.0M at $18.00
R Aug 12 Sanofi filed a Form 3 initial statement of beneficial ownership for…
X Aug 31 Short interest jumps 129.5% to 308.6K
A Sep 1 3 analysts initiate
R Sep 3 Latigo Biotherapeutics reported Q2 2026 results with a net loss of $…
X Sep 15 Short interest jumps 45.8% to 450.0K
X Sep 30 Short interest jumps 84.9% to 832.1K

Signal stack

Where each data set points today.

InsidersBULLISH

2 insiders bought $5.0M at an average $18.00. No open-market sales. Price is 15% below their cost.
AnalystsBULLISH

7 of 8 rate it Buy or better. Every target is above the price.
TrendDOWNTREND

21% below its 50-day average.

The Street

8 analysts

Buy 88% rate it Buy or better

Strong Buy3Buy4Hold1Sell0Strong Sell0

12-month targets · 4 analysts

$15.26 $36.00 $50.00 $73.00

Price is below the lowest target. Median implies +228%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Sep 1, 2026	Leerink Partners INITIATE	INITIATE	Outperform
Sep 1, 2026	Jefferies INITIATE	INITIATE	Buy
Sep 1, 2026	Guggenheim INITIATE	INITIATE	Buy

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Recent

Sep 3, 2026

Earnings

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Completed upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds…

Aug 7, 2026

Listing

New Listing: LTGO — Latigo Biotherapeutics, Inc. - Common Stock

Listed on exchange Q

Aug 6, 2026

Offering

Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering

THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company…

Insider ledger

Form 4

$5.0M

bought · 2 insiders

sold · 0 insiders

−15.2%

vs their $18.00 cost

Date	Insider	Type	Value
Aug 10, 2026	Westlake BioPartners Fund I, L.P. 10%+ Owner	CONVERT	938,979 sh
Aug 10, 2026	Westlake BioPartners Fund I, L.P. 10%+ Owner	CONVERT	1,027,635 sh
Aug 10, 2026	Westlake BioPartners Fund I, L.P. 10%+ Owner	CONVERT	3,547,842 sh
Aug 10, 2026	Westlake BioPartners Fund I, L.P. 10%+ Owner	CONVERT	1,027,635 sh
Aug 10, 2026	Westlake BioPartners Fund I, L.P. 10%+ Owner	CONVERT	165,519 sh
Aug 10, 2026	Westlake BioPartners Fund I, L.P. 10%+ Owner	CONVERT	3,464,072 sh
Aug 10, 2026	Westlake BioPartners Fund I, L.P. 10%+ Owner	CONVERT	1,484,401 sh
Aug 10, 2026	Westlake BioPartners Fund I, L.P. 10%+ Owner	CONVERT	2,066,857 sh

Earnings setup

Estimates

−$0.67

EPS estimate, this quarter

Current-quarter EPS estimate

$0.000

90d

$0.000

60d

−$0.670

30d

−$0.670

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.67	-$0.69–-$0.65	+0.0%	$0.00
Next Q	-$0.85	-$0.86–-$0.84	+0.0%	$0.00
Current FY	-$3.01	-$4.52–-$2.11	+0.0%	$0.00
Next FY	-$2.32	-$2.76–-$2.07	+0.0%	$0.00